MM120 · program

Lysergide D-tartrate (MM120 / LSD) for Generalized anxiety disorder

Phase 3ActiveDefinium Therapeutics, Inc. (DFTX)
  • Breakthrough Therapy

Indications for MM120: Generalized anxiety disorder · Phase 3 Major depressive disorder · Phase 3 Post-traumatic stress disorder · Phase 3 Attention-deficit/hyperactivity disorder · Discontinued

MM120 (DT120) for generalized anxiety disorder — lead program. FDA Breakthrough Therapy granted 7 Mar 2024 on the Phase 2b dose-finding study (NCT05407064; 100 ug gave -7.7 HAM-A vs placebo at Week 12, Cohen's d 0.81). Two pivotal Phase 3 GAD studies underway: Voyage (NCT06741228) and Panorama (NCT06809595), both active, primary completion 2026. The same compound is also Phase 3 for MDD (Emerge, NCT06941844).

Data current as of

Development timeline

Phase 3Aug 2023 – Sept 2026
  1. UpcomingPanorama, the second Phase 3 study of DT120 ODT in GAD: topline expected September 2026↗
  2. metPhase 3 Voyage topline: single-dose DT120 ODT meets primary in GAD (HAM-A −5.4 pts vs placebo at Week 12, p<0.0001)↗
  3. FinancingDefinium Therapeutics closes upsized $805M public equity offering (~$758M net) funding DT120 program↗
  4. Enrollment completeVoyage (Phase 3, DT120 ODT in GAD) completes enrollment with 214 participants↗
  5. Corporate rebrand / name changeMind Medicine (MindMed) rebrands as Definium Therapeutics↗
  6. First patient dosed in Panorama (NCT06809595), second pivotal Phase 3 GAD study.↗
  7. First patient dosed in Phase 3 Voyage (NCT06741228) — first-ever Phase 3 of LSD.↗
  8. Licensing dealCatalent grants MindMed exclusive license to Zydis ODT technology for MM-120 (lysergide)↗
Phase 2Mar 2024
  1. FDA Breakthrough Therapy Designation (GAD); positive 12-week durability data from the Phase 2b study.↗

Readouts

  • Sep 2026AnticipatedTopline data

    Panorama, the second Phase 3 study of DT120 ODT in GAD: topline expected September 2026 ↗

  • 2026-08-12ReportedTopline datamet

    Phase 3 Voyage topline: single-dose DT120 ODT meets primary in GAD (HAM-A −5.4 pts vs placebo at Week 12, p<0.0001) ↗

Clinical trials in Generalized anxiety disorder

NCT06809595PanoramaPhase 3Activen=245

Phase 3 Study of MM120 for Generalized Anxiety Disorder (Panorama)

Started Jan 2025· Primary completion Aug 2026· 📍 37 sites across 6 countries (United States, United Kingdom, France, Germany)

NCT06741228VoyagePhase 3Activen=214

Phase 3 Study of Oral DT120 vs Placebo in Generalized Anxiety Disorder (Voyage)

Started Dec 2024· Primary completion Jul 2026· 📍 34 sites across 1 country (United States)

NCT05407064Phase 2Completedn=198

Phase 2b Dose-Finding Study of MM120 for Anxiety Symptoms

Started Aug 2022· Primary completion Oct 2023· 📍 22 sites across 1 country (United States)

metprimaryHAM-A change at Week 12 (100 ug vs placebo) — -7.7 points (Cohen's d 0.81) (<0.003)

Clinical response 65%, remission 48% at Week 12.

Formulations

FormulationRouteRegimenPharmacokinetics
DT120 orally disintegrating tablet (ODT)Orally disintegrating tablet (ODT) using Catalent Zydis fast-dissolve technology
Proprietary orally disintegrating tablet of lysergide (LSD) D-tartrate; single administration; designed for faster absorption and onset
OralSingle dose—
MM120 oral (Phase 2b)
Single oral dose; 25, 50, 100, or 200 µg freebase-equivalent studied in Phase 2b GAD; 100 µg selected as optimal for pivotal trials
OralSingle dose—

Mechanism of action (compound-wide)

LSD acts across serotonin receptor subtypes; the company describes MM120 as a 5-HT2A partial agonist (IUPHAR classifies LSD as a full 5-HT2A agonist). Antidepressant effects attributed primarily to 5-HT2A agonism.

TargetActionAffinity
5-HT2AprimaryHTR2APartial agonistpKi 9.4ⓘ
5-HT1AHTR1AAgonistpKi 9ⓘ
5-HT2CHTR2CAgonistpKi 8.2ⓘ

← Full MM120 compound page (identity, identifiers, all indications)

Sources

  1. Definium Therapeutics (DFTX) maps DT120 ODT Phase 3 readouts and PTSD expansion (8-K) — Definium Therapeutics, Inc.
  2. Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder — Definium Therapeutics
  3. Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares — Definium Therapeutics, Inc.
  4. DT120 ODT — LSD Therapy for Depression and Anxiety — Definium Therapeutics
  5. First patient dosed in Voyage Phase 3 — MindMed / Definium
  6. clinicaltrials.gov — ClinicalTrials.gov
  7. ir.mindmed.co — Reference
  8. Lysergide (LSD), Ligand 17 — IUPHAR/BPS
  9. MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis Fast-Dissolve Technology for Use with MM-120 — MindMed / Definium Therapeutics
  10. MindMed FDA Breakthrough + Phase 2b durability (GAD) — MindMed / Business Wire
  11. MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 — Definium Therapeutics
  12. Panorama (NCT06809595) — ClinicalTrials.gov
  13. Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial — JAMA / PMC
  14. Voyage (NCT06741228) — ClinicalTrials.gov